10-QPeriod: Q1 FY2023

VERTEX PHARMACEUTICALS INC / MA Quarterly Report for Q1 Ended Mar 31, 2023

Filed May 2, 2023For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. reported strong financial performance for the first quarter of 2023, with net product revenues reaching $2.37 billion, a 13% increase year-over-year, driven primarily by the continued uptake of TRIKAFTA/KAFTRIO. While overall net income saw a slight decrease to $699.8 million from $762.1 million in the prior year, this was largely influenced by a significant increase in Acquired In-Process Research and Development (AIPR&D) expenses, totaling $347.1 million, up from $2.0 million in Q1 2022, reflecting substantial investments in strategic collaborations and licensing agreements. The company continues to invest heavily in its pipeline, with Research and Development expenses increasing by 24% to $742.6 million. This investment is supporting a broad range of programs targeting serious diseases beyond cystic fibrosis, including sickle cell disease, beta-thalassemia, neuropathic pain, and type 1 diabetes. Vertex also announced a new $3.0 billion share repurchase program, demonstrating a commitment to returning capital to shareholders while maintaining a robust cash position of $11.5 billion in cash, cash equivalents, and marketable securities.

Financial Highlights

47 data points
Beta

Revenue

$2.37B

88.8% Gross Margin

Net Income

$699.80M

29.5% Net Margin

EPS (Diluted)

$2.69

Total Assets

$18.97B

Cash & Equivalents

$9.29B

Free Cash Flow

$857.80M

Financial Statements
Beta
Revenue$2.37B
Cost of Revenue$266.90M
Gross Profit$2.11B
SG&A Expenses$241.10M
Operating Expenses$1.60B
Operating Income$779.00M
Net Income$699.80M
EPS (Basic)$2.72
EPS (Diluted)$2.69
Shares Outstanding (Basic)257.40M
Shares Outstanding (Diluted)260.30M

Key Highlights

  • 1Net product revenues increased by 13% to $2.37 billion, primarily driven by TRIKAFTA/KAFTRIO.
  • 2Acquired In-Process R&D expenses surged to $347.1 million from $2.0 million, reflecting significant investments in strategic collaborations (e.g., Entrada Therapeutics, CRISPR Therapeutics).
  • 3Research and Development expenses grew by 24% to $742.6 million, underscoring continued pipeline investment.
  • 4Net income decreased by 8% to $699.8 million, impacted by higher R&D and AIPR&D expenses.
  • 5The company announced a new $3.0 billion share repurchase program, indicating a focus on capital return.
  • 6Total cash, cash equivalents, and marketable securities remained strong at $11.5 billion, providing ample liquidity.
  • 7Positive clinical trial updates and regulatory submissions were noted for exa-cel (sickle cell/beta-thalassemia) and other pipeline candidates.

Frequently Asked Questions

The substantial increase in AIPR&D expenses to $347.1 million in Q1 2023 from $2.0 million in Q1 2022 is primarily due to upfront payments made for strategic collaborations and licensing agreements. Notably, these include payments to Entrada Therapeutics ($225.1 million) and CRISPR Therapeutics ($100.0 million), reflecting Vertex's strategy to acquire or license promising technologies and programs.

Vertex continues to invest heavily in R&D, with expenses increasing by 24% to $742.6 million in Q1 2023. This investment supports a diverse pipeline of small molecule, mRNA, and cell/genetic therapies across various therapeutic areas, including cystic fibrosis, sickle cell disease, type 1 diabetes, and pain. The company aims to balance risk by advancing multiple compounds and modalities to identify the most promising candidates for later-stage development.

Vertex maintains a strong liquidity position, with $11.5 billion in cash, cash equivalents, and marketable securities as of March 31, 2023. The company expects this, along with future cash flows from product sales, to be sufficient to fund operations for at least the next twelve months. Additionally, Vertex has a new $3.0 billion share repurchase program, demonstrating confidence in its financial stability and commitment to shareholder value.

TRIKAFTA/KAFTRIO continues to be the primary revenue driver, showing a 19% increase year-over-year and contributing significantly to the overall 13% revenue growth. While other CF products like KALYDECO and ORKAMBI saw revenue declines, this is attributed to patients switching to the more advanced TRIKAFTA/KAFTRIO regimen. The company is also working on label expansions for its CF medicines to cover younger age groups.